AWH: Prelim 1Q2023; Results 5/11/23 amc

Management to host its first quarter earnings conference call on Thursday, May 11 at 4:30 pm

AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced preliminary first quarter OvaSuite volume and earnings conference call details.

Preliminary First Quarter Highlights

“We are pleased with early OvaWatch adoption following the product’s launch in December 2022, which helped to drive the record 29% increase in volume for the first quarter compared to 2022,” said Nicole Sandford, CEO of Aspira Women’s Health. “We continue to see improvements in provider demand for OvaSuite. Since we launched Ova1Plus, healthcare providers have ordered more than 75,000 of our ovarian cancer risk assessment blood tests. Our sales and marketing strategies have taken shape and are improving in both effectiveness and efficiency, a trend we expect to accelerate in 2023. We look forward to sharing more information on our upcoming investor conference call scheduled for May 11, 2023 at 4:30 pm.”

Conference call & Webcast Details:
Date: Thursday, May 11
Time: 4:30 pm Eastern Time
Toll Free: 1-800-945-9434
International: 1-212-231-2937
Conference ID: 22026795
The webcast will also be available on the Events & Presentation page of the Aspira Women’s Health Investor Relations website. An archive of the webcast replay will be available on the Company’s website for up to 90 days.

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities. OvaWatch SM is a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time.

Ova1Plus ® combines our FDA-cleared products, Ova1 ® and OVERA ® , to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck™, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com .